EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.027 HKD | -3.57% |
|
0.00% | -20.59% |
| 2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
| 2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Extrawell Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Manufacturing segment is engaged in the development, manufacture and sales of pharmaceutical products. Its self-produced products include Transfer Factor Oral Solution, Wisk, ZhouBang and others. The Trading segment is engaged in the promotion and distribution of imported pharmaceuticals. Its imported products include Millibar and Skin Cap. The Gene Development segment is engaged in the commercial development and research, development of gene-related technologies.
Sector
Pharmaceuticals
Calendar
2024-06-27
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 8.57M | |
| +31.52% | 662B | |
| +21.96% | 546B | |
| -5.21% | 359B | |
| +17.02% | 323B | |
| +5.01% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.98% | 167B |
- Stock Market
- Equities
- 858 Stock
- News Extrawell Pharmaceutical Holdings Limited
- Extrawell Pharmaceutical Amends Terms of Convertible Bonds by Innovative Pharmaceutical Biotech